Meropenem Trihydrate

Meropenem Trihydrate Uses, Dosage, Side Effects, Food Interaction and all others data.

Meropenem Trihydrate
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Meropenem Trihydrate
Generic	Meropenem Trihydrate
Type
Therapeutic Class	Other beta-lactam Antibiotics
Manufacturer
Available Country	Bangladesh
Last Updated:	September 24, 2024 at 5:38 am

Uses

Meropenem is indicated for treatment in adults and children for the following infections caused by single or multiple bacteria sensitive to Meropenem. Pneumonia and Nosocomial Pneumonia Urinary Tract Infections Intra-abdominal Infections Gynaecological Infections, such as endometritis and pelvic inflammatory disease ... Read more

Dosage

Meropenem Trihydrate dosage

The dosage and duration of therapy shall be established depending on type, severity of infection and the condition of the patient. The recommended daily dosage is as follows-Adults: The usual dose is 500 mg to 1 gm by intravenous administration every 8 hours. Pneumonia, urinary tract infections, gynaecological infections such as endometritis, pelvic inflammatory disease, skin and skin structure infections: 500 mg IV every 8 hours. Nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients and septicaemia: 1 g IV every 8 hours. Intra-abdominal infections: 500 mg to 1 gm every 8 hours. Cystic fibrosis: Upto 2 gm every 8 hours. Meningitis: 2 gm IV every 8 hours. Children: 3 months to 12 years: 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogens and the condition of the patient. Intra-abdominal infections: 20 mg/kg every 8 hours. Cystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours. Meningitis: 40 mg/kg IV every 8 hours. Febrile neutropenia: 20 mg/kg every 8 hours. Children over 50 kg weight: use adult dosage. There is no experience in children with hepatic or renal impairment. Meropenem should be administered by intravenous Infusion over approximately 15-30 minutes or as intravenous bolus (5 to 20 ml) over approximately 3-5 minutes

Side Effects

Meropenem is generally well tolerated. Side effects like inflammation, thrombophlebitis, pain at the site of injection, skin reactions like rash, pruritus, urticaria, abdominal pain, nausea, vomiting, diarrhea, headache may occur.

Precaution

If an allergic reaction to Meropenem occurs, the drug should be discontinued and appropriate measures taken. Use of Meropenem in patients with hepatic disease should be made with careful monitoring of transaminase and bilirubin levels.

Interaction

Probenecid competes with Meropenem for active tubular secretion and thus inhibits the renal excretion, with the effect of increasing the elimination half-life and plasma concentration of meropenem. Meropenem may reduce serum valproic acid levels. Sub therapeutic levels may be reached in some patients.

Pregnancy & Breastfeeding use

Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. So this drug should be used during pregnancy only if clearly needed. Because many drugs are excreted in human milk, caution should be exercised when Meropenem is administered to a nursing woman.

Contraindication

Meropenem is contraindicated in patients who have demonstrated hypersensitivity to this product.

Special Warning

Renal impairment: Dosage should be reduced in patients with creatinine clearance less than 51 ml/min.Hepatic impairment: No dosage adjustments are necessary with impairment of liver function. Hemodialysis patients should receive Meropenem after dialysis has been completed.Elderly: No dosage adjustments are necessary in elderly patients unless creatinine clearance is <51 ml/min.Use in Children: Efficacy and tolerability in infants under 3 months have not been established.

Acute Overdose

Accidental overdose could occur during therapy, particularly in patients with renal impairment. Treatment of overdose should be symptomatic. In normal individuals, rapid renal elimination will occur; in subjects with renal impairment, haemodialysis will remove Meropenem and its metabolite.